11/2022Award Milestone
CONNEQT Pulse selected as CES 2023 Innovation Award Honoree
11/2022Blumio Joins CardieX Companies
CardieX Acquires Wearable Sensor Startup Blumio
06/2022Cardiex Announces CONNEQT Pulse
The World’s First Customizable Dual Blood Pressure and Arterial Health Monitor
05/2022CONNEQT app gains MDDS classification by FDA
04/2022CONNEQT Files Regulatory Submission
CONNEQT Companion App
04/2022Lisa Musatto joins the Board
03/2022Ticwatch GTH Pro Smartwatch Launched
CardieX and Mobvoi Enter the US and Australia Markets with Revolutionary Consumer Heart Heath Monitoring Smartwatch
02/2022CardieX Progresses Philip Morris Sponsored Study
02/2022New clinical trial with Andwin, Syneos and Philip Morris
06/2021Technology Milestone
ATCOR launches world’s first PPG Sensor Algorithm
06/2021ATCOR Technology Chosen for Yale University Clinical Trial
06/2021CONNECT announces LifeQ collaboration
CONNEQT Health Wearable Featuring World First Sensor Technology
05/2021New Patent
New ATCOR Patent Granted for Blood Pressure Measurement
05/2021CONNEQT Launch
New health tech company to compete with Apple and Fitbit
08/2020Expansion of Bayer Clinical Trial Contract
07/2020New Investor Placement
CardieX Successfully Completes Placement to New Investors
04/2020Major Milestone in Development
Major Milestone Development of Wearable Sensor Technology
04/2020PPG-based Algorithm Milestone
11/2019New China Distributor
10/2019Deborah Study Complete
05/2019Blumio & CardieX Present Data at IEEE
Blumio & CardieX present successful results from Macquarie University trial @ IEEE
05/2019CardieX China Established
CardieX establishes local operations in China with presence in Shanghai and Beijing
04/2019New Oscar 2 Approved in China
Oscar 2 with SphygmoCor® Inside receives China FDA approval
04/2019inHealth to use ATCOR Technology in Landmark Trial
inHealth to launch world's first trial cardiovascular program with ATCOR's SphygmoCor® technology
03/2019New China & Product Strategies
CardieX announces new strategies for next-generation product development and China market expansion
03/2019Expansion of Bayer Contract
ATCOR expands Bayer contract to provide clinical trial support for major multinational heart failure drug trial
12/2018CardieX & Blumio JDA
CardieX signs JDA with Blumio for wearable BP sensor development
12/2018Growth Capital Raised
$5.5M successfully raised in oversubscribed fundraising round
06/2018Growth Capital Raised
~5M capital raising to support new growth initiatives (with ~30% participation from Directors/C2 Ventures)
05/2018New Corporate Identity: CardieX
AtCor Medical changes name to CardieX - ASX:CDX.
05/2018AtCor Announces Wearables Trial
AtCor Medical announces wearable monitor trial in strategic partnerships with Blumio and Macquarie University
03/2018Investment in Blumio
Investment in innovative Bay Area startup focused on next-generation wearable BP sensor
03/2017A New Way Forward
New management, strategy, and Board transition to refocus on core technology and new markets
03/2016New Oscar 2 Approved in US
Oscar 2 with SphygmoCor® Inside receives FDA clearance
01/2015 CPT Code Approval in US
AMA and CMS approved introduction of CPT code 93050 for arterial pressure waveform analysis
01/2014SphygmoCor® XCEL Approved in China
China Food & Drug Administration (CFDA) approval granted for newest SphygmoCor® system
11/2012SphygmoCor® XCEL Approved in US
FDA clearance granted for newest SphygmoCor® system
07/2008SphygmoCor® CvMS Gains CE Mark
Second generation SphygmoCor® system receives CE Mark
08/2007SphygmoCor® CvMS Approved in US
FDA clearance granted for second generation SphygmoCor® system
11/2005 IPO on ASX
AtCor Medical IPOs on ASX - ASX:ACG
04/2004US Division Established
AtCor Medical, Inc. formed in the US.
2002SphygmoCor® Mx Approval in US
FDA clearance granted for first generation SphygmoCor® system
2000SphygmoCor® Mx Gains CE Mark
First generation SphygmoCor® system receives CE Mark
1996SphygmoCor® Approval in Australia
First generation SphygmoCor® system receives TGA approval
1994AtCor Medical is Born
Company founded by Dr. Michael O'Rouke - international leader in the field of cardiovascular physiology and medicine
